SubsidieMeestersSonophoresis smartpatch for pain-free, controllable, and wearable transdermal drug delivery
Wearable SmartPatch is a needle-free drug delivery system using sonophoresis to safely deliver macromolecular drugs through the skin, adaptable to various treatments and skin types.
Projectdetails
Introduction
Wearable SmartPatch is a unique needle-free drug delivery solution, based on a patented electronic system, that opens skin pores temporarily to deliver macromolecular drugs.
Technology Overview
It generates sound waves (Sonophoresis) that increase the size of the skin pores without pain or damage. This technology allows drugs like insulin, heparin, or EPO (>50KDa) to pass through, reaching the hypodermis and capillary vessels, without altering the pharmacokinetic profile of the drug.
Device Components
The device consists of:
- A durable part with a 3-year warranty, including the ultrasound generator, electronics, and battery.
- A disposable and recyclable piece that encloses the adhesive and the drug reservoir with up to 2mL (average for 3 days of treatment), which can be changed in less than 2 minutes.
Customization and Performance
The device can vary both the absorption rate and the depth reached depending on programmed stimulation parameters. This feature allows adaptation to different skin types and therapeutic uses.
Testing Results
Our tests have shown absorption rates of at least 0.05 mL/minute on a 1 cm² pig skin area.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.840.375 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- MEDICSENSORS SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMSPRISMA aims to validate a novel, ultra-compact micropump for wearable insulin delivery, enhancing accuracy and efficiency to revolutionize diabetes treatment and enable multi-drug systems. | EIC Transition | € 2.499.838 | 2022 | Details |
Piezoceutical biomaterial scaffolds for immunomodulatory-based myocardial repairThe PiezoMac patch aims to regenerate cardiac muscle post-myocardial infarction using optimized piezoelectric stimulation and 3D-printed designs tailored to patient-specific heart anatomy. | ERC COG | € 2.579.608 | 2024 | Details |
Nanoengineered photoactivated drug-free antimicrobial precision treatment for chronic skin woundsThis project aims to validate a drug-free PHOTOCURE wound patch that uses photocatalytic activity to effectively eradicate antibiotic-resistant biofilms in chronic skin infections like diabetic foot ulcers. | ERC POC | € 150.000 | 2024 | Details |
Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantificationThis project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery. | ERC POC | € 150.000 | 2025 | Details |
MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMS
PRISMA aims to validate a novel, ultra-compact micropump for wearable insulin delivery, enhancing accuracy and efficiency to revolutionize diabetes treatment and enable multi-drug systems.
Piezoceutical biomaterial scaffolds for immunomodulatory-based myocardial repair
The PiezoMac patch aims to regenerate cardiac muscle post-myocardial infarction using optimized piezoelectric stimulation and 3D-printed designs tailored to patient-specific heart anatomy.
Nanoengineered photoactivated drug-free antimicrobial precision treatment for chronic skin wounds
This project aims to validate a drug-free PHOTOCURE wound patch that uses photocatalytic activity to effectively eradicate antibiotic-resistant biofilms in chronic skin infections like diabetic foot ulcers.
Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification
This project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery.